Insights Into Renal Cell Carcinoma (RCC)
Perspectives of community physicians on the treatment of advanced renal cell carcinoma (RCC), recently introduced and upcoming agents
Faculty Chair
Neeraj Agarwal, MD
Huntsman Cancer Institute, Salt Lake City, UT
Faculty Chair
Sumanta Pal, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
Faculty Chair
Rana McKay, MD
UC San Diego Medical Center, San Diego, CA
Faculty Chair
Sumanta Pal, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
Faculty Chair
Ulka Vaishampayan, MD
Karmanos Cancer Center, Detroit, MI
Faculty Chair
Sumanta Pal, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ
Faculty Chair
Bradley McGregor, MD
Dana-Farber Cancer Institute, Boston, MA
Faculty Chair
Rana McKay, MD
UC San Diego Medical Center, San Diego, CA
More Information
- Virtual Series
- Washington, Oregon, Idaho
More Information
- Virtual Series
- California, Nevada
More Information
- Virtual Series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual Series
- Texas, Arizona, California
More Information
- Virtual Series
- Tennessee
More Information
- Virtual Series
- New York, New Jersey, Connecticut
More Information
- Virtual Series
- California, Arizona, Hawaii, Nevada
More Information
- Virtual Series
- Illinois, Iowa, Nebraska, North Dakota, South Dakota, Minnesota, Wisconsin, Michigan, Indiana, Ohio
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual Series
- National
MORE INFORMATION
- Virtual Series
- Georgia, Florida
MORE INFORMATION
- Virtual Series
- New York, Maryland, Virginia
MORE INFORMATION
- Virtual Series
- National
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of renal cell carcinoma
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors will comprise 10–15 medical oncologists representative of each region
